The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+/HER2– breast cancer, offering a new targeted first-line ...

Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) ...

Excessive protein is the current health fad. Protein is one of the three macronutrients. Fat and carbohydrates are the other two, and some experts would add fiber (a special type of carbohydrate) as a ...

WASHINGTON, 2nd June, 2025 (WAM) -- A new triple therapy for aggressive, advanced breast cancer slows the progression of the disease, delays the need for further chemotherapy and helps patients live ...

1 Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China 2 School of Pharmacy, Changchun University of Chinese Medicine, Changchun, China Depression is a psychological ...

The outlook for someone with PIK3CA-related overgrowth spectrum (PROS) depends on factors that vary from person to person. Early intervention and treatment can improve the outlook and prevent ...

Itovebi-based regimen significantly improved OS and PFS in PIK3CA-mutated, HR-positive, HER2-negative breast cancer patients. The FDA approved the Itovebi-based combination in October 2024 for ...

GAINESVILLE, Fla. — Scientists studying an aggressive cancer that affects thousands of dogs annually have uncovered a genetic signature that could hold the key to treating an extremely rare human ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...